ESMO GI 2026

ESMO GI 2026

Final analysis of DESTINY-Gastric02

wondermedia

15 July 2026

In this video, Prof Dr Eric Van Cutsem discusses the final analysis of...

ESMO GI 2026

Real-world experience with zolbetuximab in CLDN18.2-positive advanced gastric cancer

wondermedia

15 July 2026

In this video, Dr Filip Van Herpe discusses Japanese real-world data on...

ESMO GI 2026

Real-world outcomes with ivosidenib in mIDH1 cholangiocarcinoma

wondermedia

15 July 2026

Dr Amy de Haar-Holleman discusses a real-world chart review study evaluating...

ESMO GI 2026

Mismatch repair status and outcomes in locally advanced rectal cancer treated with total neoadjuvant therapy

wondermedia

15 July 2026

In this video, Dr Nada Benhima presents a real-world analysis evaluating the...

ESMO GI 2026

KRAS status in pancreatic ductal adenocarcinoma

wondermedia

15 July 2026

In this video, Dr Justine Castaigne discusses a retrospective analysis of KRAS...

ESMO GI 2026

Immune-mediated adverse events in MATTERHORN

wondermedia

15 July 2026

In this video, Dr Filip Van Herpe discusses a poster presented at ESMO GI 2026...

ESMO GI 2026

Neoadjuvant immunotherapy in HCC: recurrence patterns and treatment sequencing

wondermedia

15 July 2026

Dr Sarah Cappuyns discusses a patient-level pooled analysis of phase I/II...

ESMO GI 2026

Actionable biomarker co-expression in G/GEJ cancer

wondermedia

15 July 2026

In this video, Dr Filip Van Herpe speaks with Dr Rutika Mehta to discuss a...

ESMO GI 2026

Long-term benefit of ivosidenib in IDH1-mutated cholangiocarcinoma

wondermedia

15 July 2026

In this video, Prof Dr Arndt Vogel discusses updated results from the phase...

ESMO GI 2026

Upfront S-1-based chemotherapy in GI cancer patients with severe cardiac comorbidity: a European case series

wondermedia

15 July 2026

In this video, Dr Gertjan Rasschaert discusses with Prof Dr Pia Österlund the...